MA46337B1 - Composé de pyridine - Google Patents

Composé de pyridine

Info

Publication number
MA46337B1
MA46337B1 MA46337A MA46337A MA46337B1 MA 46337 B1 MA46337 B1 MA 46337B1 MA 46337 A MA46337 A MA 46337A MA 46337 A MA46337 A MA 46337A MA 46337 B1 MA46337 B1 MA 46337B1
Authority
MA
Morocco
Prior art keywords
pyridine compound
pharmaceutically acceptable
acceptable salt
relates
compound
Prior art date
Application number
MA46337A
Other languages
English (en)
Other versions
MA46337A (fr
Inventor
Hiroaki Inagaki
Yoshihiro Shibata
Hidenori Namiki
Hideaki Kageji
Kiyoshi Nakayama
Yasuyuki Kaneta
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of MA46337A publication Critical patent/MA46337A/fr
Publication of MA46337B1 publication Critical patent/MA46337B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne un composé ayant une action inhibitrice de la kinase ret ou un sel pharmaceutiquement acceptable de celui-ci, utile dans le traitement de maladies telles que le cancer. En particulier, l'invention concerne un composé représenté par la formule générale (i) suivante telle que définie dans la description : (i) ou un sel pharmaceutiquement acceptable de celui-ci.
MA46337A 2016-09-29 2017-09-28 Composé de pyridine MA46337B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016191725A JP2018052878A (ja) 2016-09-29 2016-09-29 ピリジン化合物
PCT/GB2017/052913 WO2018060714A1 (fr) 2016-09-29 2017-09-28 Composé de pyridine

Publications (2)

Publication Number Publication Date
MA46337A MA46337A (fr) 2019-08-07
MA46337B1 true MA46337B1 (fr) 2021-04-30

Family

ID=60020249

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46337A MA46337B1 (fr) 2016-09-29 2017-09-28 Composé de pyridine
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054910A MA54910A (fr) 2016-09-29 2017-09-28 Sels de pyridine et procédé

Country Status (33)

Country Link
US (2) US10851092B2 (fr)
EP (2) EP3828178A1 (fr)
JP (2) JP2018052878A (fr)
KR (1) KR102520543B1 (fr)
CN (2) CN110036007B (fr)
AU (2) AU2017335242C1 (fr)
BR (1) BR112019006047A2 (fr)
CA (1) CA3035860A1 (fr)
CL (1) CL2019000844A1 (fr)
CO (1) CO2019004034A2 (fr)
CY (1) CY1123988T1 (fr)
DK (1) DK3519398T3 (fr)
EA (1) EA037103B1 (fr)
EC (1) ECSP19030134A (fr)
ES (1) ES2868748T3 (fr)
HR (1) HRP20210447T1 (fr)
HU (1) HUE054824T2 (fr)
IL (1) IL265630B (fr)
LT (1) LT3519398T (fr)
MA (2) MA46337B1 (fr)
MD (1) MD3519398T2 (fr)
MX (1) MX2019003747A (fr)
PE (1) PE20190805A1 (fr)
PH (1) PH12019500480A1 (fr)
PL (1) PL3519398T3 (fr)
PT (1) PT3519398T (fr)
RS (1) RS61640B1 (fr)
SG (1) SG11201901937WA (fr)
SI (1) SI3519398T1 (fr)
SM (1) SMT202100315T1 (fr)
UA (1) UA123964C2 (fr)
WO (1) WO2018060714A1 (fr)
ZA (1) ZA201902232B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787018B (zh) 2015-11-02 2022-12-11 美商纜圖藥品公司 轉染過程重排之抑制劑
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
US11603374B2 (en) 2018-01-18 2023-03-14 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
CA3096043A1 (fr) 2018-04-03 2019-10-10 Blueprint Medicines Corporation Inhibiteur de ret destine a etre utilise dans le traitement du cancer presentant une alteration du ret
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
MX2022005991A (es) * 2019-11-18 2022-06-17 Chugai Pharmaceutical Co Ltd Farmaco combinado.
CN113121524B (zh) 2019-12-31 2023-04-25 南京创济生物医药有限公司 杂环亚砜亚胺化合物及其中间体、制备方法和应用
WO2021148581A1 (fr) 2020-01-22 2021-07-29 Onxeo Nouvelle molécule dbait et son utilisation
JP7461605B2 (ja) * 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
WO2021164741A1 (fr) * 2020-02-20 2021-08-26 南京明德新药研发有限公司 Composé de bisamide de phényle
CA3183728A1 (fr) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Formes solide de pralsetinib
WO2022238706A1 (fr) 2021-05-14 2022-11-17 Bp Asset Viii, Inc. Inhibiteur de ret pour le traitement du cancer médullaire de la thyroïde à altération de ret ou du cancer du poumon non à petites cellules à altération de ret
US20230233691A1 (en) 2021-10-22 2023-07-27 University Of Houston System Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancers of epithelial tissues
CN115090331B (zh) * 2022-07-21 2023-05-16 扬州大学 超分子手性催化剂、其制备方法及其催化d-a反应的应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CN102060806A (zh) 2003-09-11 2011-05-18 iTherX药品公司 细胞因子抑制剂
WO2007099317A1 (fr) 2006-03-02 2007-09-07 Astrazeneca Ab Dérivés de la quinazoline
WO2007099323A2 (fr) 2006-03-02 2007-09-07 Astrazeneca Ab Dérivés de la quinoline
WO2007113565A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de la naphtyridine comme agents anti-cancéreux
WO2007113548A1 (fr) 2006-04-06 2007-10-11 Astrazeneca Ab Dérivés de naphtyridine
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
AU2010218748B2 (en) * 2009-02-27 2015-03-26 Teijin Limited Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
KR20120053052A (ko) 2009-08-25 2012-05-24 아브락시스 바이오사이언스, 엘엘씨 헤지호그 억제제 및 탁산의 나노입자 조성물로의 조합 요법
BR112012026644A2 (pt) 2010-04-23 2017-12-19 Kineta Inc compostos antivirais
WO2012082817A1 (fr) 2010-12-16 2012-06-21 Boehringer Ingelheim International Gmbh Inhibiteurs biarylamide de production de leukotriènes
EP2872493B1 (fr) 2012-07-13 2018-11-14 Indiana University Research and Technology Corporation 5,6,7-trimethoxy 4-phenyle quinoline-2-ones utilisables en vue du traitement de l'amyotrophie spinale
UA115264C2 (uk) * 2013-03-15 2017-10-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Піридинові похідні як інгібітори реаранжованої у процесі трансфекції (ret) кінази
RU2016111675A (ru) * 2013-08-30 2017-10-04 Эмбит Байосайенсиз Корпорейшн Соединения биарилацетамида и способы их применения
GB201321146D0 (en) 2013-11-29 2014-01-15 Cancer Rec Tech Ltd Quinazoline compounds
WO2015163435A1 (fr) * 2014-04-24 2015-10-29 田辺三菱製薬株式会社 Nouveaux dérivés de 2-amino-pyridine et 2-amino-pyrimidine et leur utilisation médicinale
JP6538153B2 (ja) * 2014-09-10 2019-07-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｒｅａｒｒａｎｇｅｄ ｄｕｒｉｎｇ ｔｒａｎｓｆｅｃｔｉｏｎ（ｒｅｔ）阻害剤としての新規な化合物
RS58813B1 (sr) * 2014-09-10 2019-07-31 Glaxosmithkline Ip Dev Ltd Piridonski derivati korišćeni kao inhibitori kinaze reorganizovane tokom transfekcije (ret)
JP6899323B2 (ja) 2014-10-14 2021-07-07 ラ ホーヤ インスティテュート オブ アレルギー アンド イミュノロジー 低分子量タンパク質チロシンホスファターゼの阻害剤、及びその使用
CN104844589B (zh) 2014-12-26 2018-04-20 中国科学院合肥物质科学研究院 一种pi3k激酶抑制剂
US10202365B2 (en) * 2015-02-06 2019-02-12 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors
JP6816100B2 (ja) 2015-07-16 2021-01-20 アレイ バイオファーマ、インコーポレイテッド ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物
JP2018052878A (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物

Also Published As

Publication number Publication date
SG11201901937WA (en) 2019-04-29
EP3519398B1 (fr) 2021-02-24
EP3519398A1 (fr) 2019-08-07
CN110036007B (zh) 2021-10-15
DK3519398T3 (da) 2021-03-29
EP3828178A1 (fr) 2021-06-02
ECSP19030134A (es) 2019-08-30
AU2017335242A1 (en) 2019-05-02
HUE054824T2 (hu) 2021-10-28
CA3035860A1 (fr) 2018-04-05
UA123964C2 (uk) 2021-06-30
RS61640B1 (sr) 2021-04-29
JP2018052878A (ja) 2018-04-05
PT3519398T (pt) 2021-03-24
US20210163464A1 (en) 2021-06-03
KR20190086442A (ko) 2019-07-22
ZA201902232B (en) 2022-12-21
LT3519398T (lt) 2021-05-10
MA54910A (fr) 2022-04-13
CN113788824A (zh) 2021-12-14
AU2021261899A1 (en) 2021-12-02
MX2019003747A (es) 2019-09-19
SMT202100315T1 (it) 2021-07-12
US10851092B2 (en) 2020-12-01
CO2019004034A2 (es) 2019-07-10
SI3519398T1 (sl) 2021-07-30
CN110036007A (zh) 2019-07-19
ES2868748T3 (es) 2021-10-21
CL2019000844A1 (es) 2019-06-07
EA201990833A1 (ru) 2019-10-31
JP7098609B2 (ja) 2022-07-11
AU2017335242B2 (en) 2021-08-19
PE20190805A1 (es) 2019-06-10
JP2019534871A (ja) 2019-12-05
MD3519398T2 (ro) 2021-05-31
HRP20210447T1 (hr) 2021-07-23
IL265630A (en) 2019-05-30
KR102520543B1 (ko) 2023-04-10
PL3519398T3 (pl) 2021-06-28
PH12019500480A1 (en) 2019-08-05
WO2018060714A1 (fr) 2018-04-05
BR112019006047A2 (pt) 2019-06-25
CY1123988T1 (el) 2022-05-27
US20200039974A1 (en) 2020-02-06
EA037103B1 (ru) 2021-02-05
MA46337A (fr) 2019-08-07
IL265630B (en) 2021-10-31
AU2017335242C1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
MA46337A (fr) Composé de pyridine
MA58087B1 (fr) Nouveaux dérivés de méthylquinazolinone
MY191110A (en) Pyrazolopyrimidine derivatives as kinase inhibitor
MA52948B1 (fr) Composés
MA38390A1 (fr) Composés tétrahydropyrrolothiazines
SA520412335B1 (ar) مشتقات أوكسي فلورو ببريدين كمثبط كيناز
MA35861B1 (fr) Inhibiteur de la kinase régulant les signaux de l'apoptose
EA201890473A1 (ru) Гетероарильные производные в качестве ингибиторов parp
MA38454B1 (fr) Inhibiteurs de protéines kinases
MX391812B (es) Agonista fxr derivado de esteroides.
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
CL2017003032A1 (es) Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste
MX375323B (es) Inhibidores de cinasa de interacción con proteína cinasa activada por mitógeno (mnk) y métodos relacionados con los mismos.
TN2020000125A1 (en) Amino-fluoropiperidine derivative as kinase inhibitor
EA201792478A1 (ru) Соединения-ингибиторы передачи сигналов пути notch
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
MA39983B1 (fr) Dérivés de carboxamide
NZ746906A (en) Oxaborole esters and uses thereof
EA201692557A1 (ru) Хинолизиноновые производные в качестве ингибиторов pi3k
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
SA523451905B1 (ar) Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات
MX2021007258A (es) Composiciones de esparsentan amorfas.
MA50093B1 (fr) Composé pentacyclique
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain
MA40605B1 (fr) Composé pyrazolothiazole et médicament